FBT: AI 评分 47/100 — AI 分析 (4月 2026)

First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund seeking to replicate the performance of the NYSE Arca Biotechnology Index. The fund provides investors targeted exposure to the biotechnology sector through a diversified portfolio of publicly traded companies.

Key Facts: AI Score: 47/100 Sector: Financial Services

公司概况

概要：

First Trust NYSE Arca Biotechnology Index Fund (FBT) offers investors exposure to the biotechnology sector by tracking the NYSE Arca Biotechnology Index. With a market capitalization of $1.22 billion, FBT provides a diversified portfolio of biotech companies, appealing to investors seeking targeted sector exposure within the financial services industry.

FBT是做什么的？

The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) designed to mirror the performance of the NYSE Arca Biotechnology Index. Launched with the objective of providing investors with targeted exposure to the biotechnology sector, FBT offers a diversified portfolio of companies involved in various aspects of biotechnology, including research, development, manufacturing, and marketing of biopharmaceutical products. The fund operates under the umbrella of First Trust, a well-established asset management firm known for its diverse range of ETF offerings. FBT's investment strategy focuses on replicating the index's composition, holding stocks in proportion to their weightings in the underlying index. This passive management approach aims to deliver returns that closely align with the performance of the biotechnology sector as a whole. By investing in FBT, investors gain access to a broad spectrum of biotech companies, ranging from established industry leaders to emerging growth firms. The fund's holdings span various therapeutic areas, including oncology, immunology, genetic engineering, and drug delivery technologies. FBT's geographic focus is primarily on companies listed on U.S. stock exchanges, reflecting the composition of the NYSE Arca Biotechnology Index. As an ETF, FBT offers investors several advantages, including intraday liquidity, transparency, and cost-effectiveness. The fund's shares are traded on major stock exchanges, allowing investors to buy or sell shares throughout the trading day. FBT's expense ratio reflects the cost of managing the fund, including administrative fees and operating expenses.

FBT的投资论点是什么？

FBT presents a targeted investment vehicle for those seeking exposure to the biotechnology sector. With a beta of 0.92, the fund exhibits market correlation. The primary value driver is the performance of the underlying NYSE Arca Biotechnology Index, which is influenced by factors such as drug approvals, clinical trial results, and regulatory changes. Upcoming catalysts include potential advancements in gene editing technologies and increased healthcare spending. However, potential risks include regulatory hurdles, clinical trial failures, and market volatility affecting the biotechnology sector. the may be worth researching fund's concentration in the biotechnology industry and its sensitivity to sector-specific events.

FBT在哪个行业运营？

FBT operates within the asset management industry, specifically focusing on exchange-traded funds (ETFs) that track specific indices. The biotechnology sector is characterized by high growth potential driven by advancements in medical technology and an aging global population. However, it also faces significant regulatory hurdles and high research and development costs. FBT competes with other biotechnology ETFs and actively managed funds, offering investors a passive investment approach to gain exposure to this dynamic sector. The market size of the biotechnology industry is substantial, with significant growth projected in the coming years.

Asset Management

Financial Services

FBT有哪些增长机遇？

Increased Healthcare Spending: The global healthcare expenditure is projected to rise significantly, driven by aging populations and increased access to healthcare services. This trend creates opportunities for biotechnology companies to develop and market innovative therapies, driving demand for FBT as a vehicle for investing in the sector. This growth is expected to continue through 2030, providing a long-term tailwind for FBT's performance.
Advancements in Gene Editing Technologies: Gene editing technologies such as CRISPR-Cas9 hold immense potential for treating genetic diseases and developing personalized medicine. As these technologies mature and gain regulatory approval, biotechnology companies involved in gene editing are expected to experience significant growth, boosting the value of FBT's portfolio. The timeline for widespread adoption of gene editing therapies is estimated to be within the next 5-10 years.
Drug Approvals and Clinical Trial Successes: Positive clinical trial results and new drug approvals are major catalysts for biotechnology companies. Successful drug development can lead to significant revenue growth and market capitalization increases, benefiting FBT's investors. The FDA approval process remains a key factor, with ongoing monitoring of clinical trial data and regulatory decisions.
Expansion into Emerging Markets: Emerging markets represent a significant growth opportunity for biotechnology companies. As healthcare infrastructure improves and access to medicines expands in these regions, demand for innovative therapies is expected to increase, driving revenue growth for companies held in FBT's portfolio. This expansion is projected to occur over the next decade, with varying timelines depending on the specific market.
Strategic Acquisitions and Partnerships: Mergers and acquisitions (M&A) activity within the biotechnology sector can create value for shareholders. Strategic acquisitions can lead to synergies, expanded product portfolios, and increased market share, benefiting FBT's investors. Ongoing: The biotechnology industry is characterized by frequent M&A activity, with larger companies acquiring smaller, innovative firms to bolster their pipelines and capabilities.

Market capitalization of $1.22 billion indicates substantial investor interest in the biotechnology sector.
Beta of 0.92 suggests moderate volatility relative to the broader market.
The fund's investment objective is to replicate the price and yield of the NYSE Arca Biotechnology Index, providing targeted exposure to the biotechnology sector.
FBT's expense ratio reflects the cost of managing the fund, including administrative fees and operating expenses.
The fund's holdings span various therapeutic areas, including oncology, immunology, genetic engineering, and drug delivery technologies.

FBT提供哪些产品和服务？

Replicates the performance of the NYSE Arca Biotechnology Index.
Provides investors with targeted exposure to the biotechnology sector.
Offers a diversified portfolio of biotechnology companies.
Invests in companies involved in research, development, manufacturing, and marketing of biopharmaceutical products.
Trades on major stock exchanges, providing intraday liquidity.
Operates as an exchange-traded fund (ETF).

FBT如何赚钱？

Replicates the NYSE Arca Biotechnology Index by holding stocks in proportion to their weightings in the index.
Generates revenue through management fees charged to investors.
Offers a passive investment approach, aiming to deliver returns that closely align with the performance of the biotechnology sector.

Retail investors seeking exposure to the biotechnology sector.
Institutional investors looking for a diversified investment in biotech companies.
Financial advisors seeking to provide clients with targeted sector exposure.
Hedge funds and other sophisticated investors.

Index-tracking methodology provides a cost-effective way to gain exposure to the biotechnology sector.
Diversified portfolio reduces risk compared to investing in individual biotech stocks.
Liquidity and transparency of an exchange-traded fund.
Established brand and reputation of First Trust as an asset manager.

什么因素可能推动FBT股价上涨？

Upcoming: Potential advancements in gene editing technologies.
Ongoing: Increased healthcare spending globally.
Ongoing: Drug approvals and clinical trial successes.
Ongoing: Mergers and acquisitions within the biotechnology sector.
Upcoming: Expansion into emerging markets.

FBT的主要风险是什么？

Potential: Regulatory hurdles and delays in drug approvals.
Potential: Clinical trial failures.
Ongoing: Competition from other biotechnology ETFs and actively managed funds.
Ongoing: Market volatility and economic downturns.
Potential: Intellectual property disputes and patent challenges.

FBT的核心优势是什么？

Targeted exposure to the high-growth biotechnology sector.
Diversified portfolio reduces company-specific risk.
Liquidity and transparency of an ETF.
Passive management approach provides cost-effectiveness.

FBT的劣势是什么？

Concentration in the biotechnology sector makes it vulnerable to sector-specific risks.
Performance is dependent on the performance of the underlying index.
Subject to regulatory and clinical trial risks associated with the biotechnology industry.
No dividend yield.

FBT有哪些机遇？

Growth in the biotechnology sector driven by advancements in medical technology.
Increasing healthcare spending globally.
Potential for new drug approvals and clinical trial successes.
Expansion into emerging markets.

FBT面临哪些威胁？

Regulatory hurdles and delays in drug approvals.
Clinical trial failures.
Competition from other biotechnology ETFs and actively managed funds.
Market volatility and economic downturns.

FBT的竞争对手是谁？

ClearBridge Energy Midstream ETF — Focuses on energy midstream companies. — (CGIE)
First Trust Mid Cap Core AlphaDEX ETF — Tracks a fundamentally weighted index of mid-cap stocks. — (FNX)
First Trust Large Cap Core AlphaDEX ETF — Tracks a fundamentally weighted index of large-cap stocks. — (FTA)
First Trust Value Line Dividend Index Fund — Tracks the Value Line Dividend Index. — (FVAL)
Global X FTSE Greece 20 ETF — Focuses on Greek equities. — (GPIX)

Key Metrics

Volume: 0
MoonshotScore: 47/100

AI Insight

AI analysis pending for FBT

常见问题

What does First Trust NYSE Arca Biotechnology Index Fund do?

First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund (ETF) that seeks to replicate the performance of the NYSE Arca Biotechnology Index. It provides investors with a convenient way to gain exposure to a diversified portfolio of biotechnology companies. The fund invests in companies involved in various aspects of the biotechnology industry, including research, development, manufacturing, and marketing of biopharmaceutical products. FBT aims to track the index's performance, offering investors returns that closely align with the overall biotechnology sector.

What do analysts say about FBT stock?

AI analysis is pending for FBT. Generally, analysts covering biotechnology ETFs focus on factors such as the fund's expense ratio, tracking error, and the performance of its underlying index. Key valuation metrics include the fund's price-to-earnings ratio and price-to-book ratio, which reflect the valuation of the biotechnology companies held in the portfolio. Growth considerations include the potential for new drug approvals, clinical trial successes, and advancements in medical technology. The pending AI analysis will provide further insights into FBT's investment potential.

What are the main risks for FBT?

The main risks for FBT are inherent to the biotechnology sector. Regulatory hurdles and delays in drug approvals can significantly impact the performance of biotechnology companies. Clinical trial failures are another major risk, as they can lead to substantial losses for companies developing new therapies. Market volatility and economic downturns can also negatively affect the biotechnology sector, as investors may become risk-averse and reduce their exposure to growth-oriented industries. Competition from other biotechnology ETFs and actively managed funds is also a factor.

How does First Trust NYSE Arca Biotechnology Index Fund make money in financial services?

First Trust NYSE Arca Biotechnology Index Fund generates revenue primarily through management fees. These fees are charged to investors as a percentage of the fund's assets under management (AUM). The fund's expense ratio reflects the total cost of managing the fund, including management fees, administrative expenses, and other operating costs. The higher the AUM, the more revenue the fund generates for First Trust. As an index fund, FBT does not actively trade securities to generate profits; instead, it focuses on replicating the performance of the NYSE Arca Biotechnology Index.

How is First Trust NYSE Arca Biotechnology Index Fund adapting to fintech disruption?

As an ETF provider, First Trust is adapting to fintech disruption by leveraging technology to enhance its investment products and services. This includes developing sophisticated algorithms for portfolio construction and risk management, as well as utilizing data analytics to gain insights into market trends and investor behavior. First Trust is also embracing digital distribution channels to reach a wider audience of investors and provide them with convenient access to its ETF offerings. The company's focus on innovation and technology is helping it remain competitive in the rapidly evolving financial services industry.

Is FBT a good investment right now?

Use the AI score and analyst targets on this page to evaluate First Trust NYSE Arca Biotechnology Index Fund (FBT). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for FBT?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates First Trust NYSE Arca Biotechnology Index Fund across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find FBT financial statements?

First Trust NYSE Arca Biotechnology Index Fund financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.